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Background/aim: Colistin is used as a salvage therapy for multidrug-resistant and extremely drug-resistant gram-negative bacterial
infections. Our aim was to evaluate colistin efficiency and toxicity in the treatment of these resistant gram-negative bacterial infections.
Materials and methods: This is a retrospective study carried out in a tertiary care hospital during 2011–2013. Study data were collected
from the medical records and consultations of the infectious diseases clinic.
Results: The study group included 158 patients with nosocomial infections and 136 (86.1%) of them were hospitalized in the ICU.
Respiratory tract infections were the most commonly observed ones (n = 103, 65.2%). The most frequently isolated microorganism
was Acinetobacter baumannii (72.2%). A total of 98 (62.0%) patients had clinical cure. There was no statistically significant difference
between monotherapy (n = 3/6, 50.0%) and combination therapies (n = 95/152, 62.5%) according to clinical response. Underlying
ultimately fatal disease, previous renal disease, and total parenteral nutrition were independent risk factors for poor clinical response.
Nephrotoxicity developed in 80 (50.6%) patients and clinical cure was statistically unrelated with nephrotoxicity.
Conclusion: Colistin may be used as an effective agent for multidrug-resistant and extremely drug-resistant gram-negative bacterial
infections with close monitoring of renal functions, especially for older and critically ill patients.
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1. Introduction
The polymyxin group of polypeptide antibiotics is among
the first antibiotics, discovered in the 1940s, with significant
activity against gram-negative bacteria. Both polymyxin E
(colistin) and polymyxin B were used clinically. Following
reports on nephrotoxicity and neurotoxicity in the 1970s,
other antibiotics were used instead of them. In the last
decade, this group was reconsidered as a therapeutic
option for multidrug-resistant/extremely drug-resistant
gram-negative (MDR/XDR-GN) bacterial infections and
particularly for the carbapenem-resistant Acinetobacter
species (1,2).
After its reintroduction in medical practice in the
last 5 years, studies focused on the effectiveness and
the side effects of colistin, especially nephrotoxicity.
Nephrotoxicity after intravenous colistin treatment was
observed at rates of 6%–58% in recent studies. Rates of
10%–27% and 58% were found in patients with basal
normal and abnormal renal functions, respectively (3,4).

The difference in the nephrotoxicity rates was explained
by various definitions of acute kidney injury. Some studies
used RIFLE criteria (risk, injury, failure, loss, and endstage kidney disease), while some used the threshold
of failure or creatinine level of more than 2 mg/dL. Risk
factors for nephrotoxicity were older age, preexisting renal
insufficiency, hypoalbuminemia, hyperbilirubinemia, and
concomitant use of nonsteroidal antiinflammatory drugs,
calcineurin inhibitors, or other nephrotoxic agents like
vancomycin (1,5,6).
In this study, the efficiency against nosocomial MDR/
XDR-GN bacterial infections and risk of nephrotoxicity
with intravenous colistin treatment were investigated.
2. Materials and methods
2.1. Study design
This retrospective study includes the records of patients
treated with intravenous colistin between January 2011
and February 2013 in Celal Bayar University Hospital in
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Manisa, Turkey, a tertiary care hospital with 585 beds.
Patients older than 18 who had been treated for nosocomial
MDR/XDR-GN bacterial infections with intravenous
colistin for at least 72 h were included.
The patients were treated with colistin (Colimycin,
Koçak Farma, Turkey; each vial contained 150 mg of
colistin base activity). We administered a daily IV colistin
dosage of 2.5–5 mg/kg (base activity), divided into two
or three doses in patients with normal renal function.
The total daily dosage was modified for renal impairment
according to the manufacturer’s instructions. A loading
dose for colistin had not been recommended at the time
the study was conducted, so a loading dose was not given
to the study patients.
2.2. Data collection
Study data were collected with a standardized form from
the medical records and consultations of the infectious
diseases clinic.
The variables of the patients including age, sex,
hospitalization wards, underlying disease determined
according to the classification of McCabe and Jackson
(7), duration of hospital and intensive care unit (ICU)
stay, type of infection, recent surgical or other invasive
procedures, presence of risk factors, empiric antibiotic
therapy, duration and dosage of colistin treatment, and
outcome were recorded.
Risk factors affecting clinical response during
hospitalization were defined as the following conditions:
surgery (within 2 weeks prior to the infection episode),
total parenteral nutrition, mechanical ventilation (during
the infection diagnosis period), previous antibiotic therapy
(within 2 weeks prior to infection), hemodialysis (during
the hospital stay), and corticosteroid therapy (prednisone
at 20 mg daily for at least 2 weeks or 30 mg daily for at least
1 week before the infection episode).
2.3. Definitions
According to the McCabe and Jackson classification,
patients were categorized as 0, no underlying disease; 1,
nonfatal underlying disease; 2, ultimately fatal underlying
disease; and 3, rapidly fatal disease.
Renal side effects of colistin were evaluated according
to the RIFLE classification system (8). This system uses
three severity categories (risk, injury, and failure) and two
outcome categories (complete loss of kidney function and
end-stage kidney disease).
Nosocomial infections were diagnosed according to
CDC definitions (9).
Isolated bacteria were identified by the API 20NE
system. Antimicrobial resistance of isolates was studied by
disk diffusion test and interpreted according to the criteria
suggested by the Clinical Laboratory Standards Institute.
Isolates nonsusceptible to ≥1 agent in ≥3 antimicrobial
categories were accepted as multidrug-resistant (MDR)
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bacteria. Those nonsusceptible to ≥1 agent in all but ≤2
antimicrobial categories were accepted as extremely
drug-resistant (XDR) bacteria. Antibiotic categories were
evaluated according to the isolated bacteria (10).
Clinical cure was defined as the resolving of signs
and symptoms of infections and laboratory findings, and
eradication of the isolated microorganisms in subsequent
cultures from the original infection site was determined
as microbiological cure. Therapeutic failure was defined
as persistence or worsening of signs and symptoms of
infection after colistin therapy.
2.4. Statistical analysis
The results were analyzed using SPSS 15.0 for Windows.
Categorical variables were analyzed using chi-square or
Fisher exact tests. The association between factors and
cure was analyzed using a logistic regression model. The
odds ratios (ORs) with 95% confidence intervals were
presented. All P-values were 2-tailed and P < 0.05 was
considered as statistically significant.
3. Results
3.1. Study population
In the study period, 158 patients fulfilled the inclusion
criteria. The study group included 111 (70.3%) male and
47 (29.7%) female patients with a mean age of 58.2 years
(range: 18–92). Among these, 136 patients (86.1%) were
hospitalized in the ICU with a mean duration of 36.80 ±
26.75 days.
According to the McCabe and Jackson classification,
29 (18.4%) patients had no underlying diseases, while
they were nonfatal for 71 (44.9%), ultimately fatal for 55
(34.8%), and rapidly fatal for 3 (1.9%) patients.
The most common predisposing conditions were
as follows: diabetes mellitus (n = 35, 22.2%), cardiac
disease (n = 38, 24.1%), chronic pulmonary disease (n
= 41, 25.9%), and solid malignancy (n = 29, 18.3%). The
presence of other conditions, including hematological
malignancy, neurological disorders, connective tissue
disease, and chronic liver disease, was infrequent.
3.2. Infections
All infections were nosocomial. There were 103 cases of
respiratory tract infections (65.2%), 21 cases of blood
stream infections (13.3%), 12 surgical infections (7.6%),
9 cases of urinary infections (5.7%), and 13 infections of
other sites (8.2%). Among the respiratory tract infections,
76 (48.1%) infections were ventilator-associated
pneumonia.
There were 130 (72.2%) cases of Acinetobacter
baumannii, 40 (22.2%) of Pseudomonas aeruginosa, 9
(5.0%) of Klebsiella pneumoniae, and 1 (0.6%) of E. coli
isolated. In 22 (13.9%) cases both Acinetobacter baumannii
and Pseudomonas aeruginosa isolations were determined.
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According to the susceptibility results, isolated strains
were grouped as MDR and XDR and these results are
shown in Table 1.
3.3. Colistin treatment and outcome
The mean duration of colistin administration was 16.4
± 11.96 days (median: 14.5). The median duration of
hospitalization prior to colistin treatment was 18.47 ±
13.32 days (range: 3–67 days).
Six patients (3.8%) were administrated only colistin.
Dual and triple combination therapies were given to 64
(40.5%) and 88 (55.7%) patients, respectively. Clinical cure
was determined in 98 (62.0%) and microbiological cure
was determined in 55 (34.8%) patients. Monotherapy and
dual and triple therapy were statistically compared with
microbiological and clinical cure and no significance was
determined (respectively, P = 0.560, P = 0.826). The most
commonly added antibiotic group was carbapenem (n =
79, 32.9%). The other groups were beta-lactams other than
carbapenems (n = 62, 25.8%), aminoglycosides (n = 52,
21.7%), quinolones (n = 28, 11.7%), and tigecycline (n =
19, 7.9%). There was no significance when carbapeneminvolving combinations (n = 79) were compared with
other combinations according to microbiological and
clinical cure rates (P = 0.168, P = 0.437, chi-square test).
In the carbapenem-involving combination group,
microbiological cure was 29.1% (n = 23) and clinical cure
was 58.2% (n = 46), while cure rates in the other antibiotic
group were 39.7% (n = 29) and 64.4% (n = 47), respectively.
Univariate analyses were performed to determine
the factors for clinical response in patients with colistin
treatment. Factors significantly associated with poor
clinical response were older age (≥65 years), total parenteral
nutrition, hospitalization in the ICU, underlying ultimately
fatal disease, previous renal disease, hemodialysis, and
previous antibiotic usage. The characteristics of patients
and the relationships of risk factors with clinical response
are shown in Table 2 and microbiological and clinical cure
rates of colistin therapy are summarized in Table 3.

Statistically significant variables were also analyzed
with a logistic regression model. Underlying ultimately
fatal diseases, underlying renal diseases, and total
parenteral nutrition were determined as independent risk
factors for poor clinical response with colistin treatment
of MDR/XDR-GN infections by this multivariate analysis.
Results are shown in Table 4.
3.4. Adverse reactions
According to the RIFLE classification, nephrotoxicity
developed in 80 (50.6%) patients during colistin
treatment. Among them, 14 (17.5%), 20 (25.0%), and 46
(57.5%) patients developed renal impairment within risk,
injury, and failure categories, respectively. Nephrotoxicity
developed after 11.23 ± 11.10 days (median: 9).
In these patients, renal function tests returned to
baseline levels in 21 (26.25%) patients with colistin
dose reduction and in 35 (43.75%) patients with the
discontinuation of the therapy.
When risk factors related to nephrotoxicity during
colistin therapy were evaluated with univariate analyses,
only older age (≥65 years) was found to be statistically
significant (P = 0.003, Fisher exact test). Usage of other
nephrotoxic drugs, underlying renal disease, and colistin
dosage were not found as significant risk factors. The
relationship between colistin nephrotoxicity and clinical
response was not found to be significant (P = 0.130, Fisher
exact test). Results are shown in Table 2.
We could not evaluate the neurologic adverse
reactions of 136 patients hospitalized in ICU because of
unconsciousness and sedated condition. No neurotoxicity
was determined in the remainder of patients.
4. Discussion
The effectiveness of colistin for treating MDR/XDR-GN
bacterial infections was shown in several studies and most
of them were carried out in ICUs. The clinical response
reported in these studies varied between 45% and 88%
(11–16). There was a wide range of clinical outcomes,

Table 1. Susceptibility of the isolated organisms.
Susceptibility

XDR
n (%)a

MDR
n (%)a

Total

Acinetobacter baumannii

120 (92.3)

10 (7.7)

130

Pseudomonas aeruginosa

27 (67.5)

13 (32.5)

40

Klebsiella pneumoniae

9 (100.0)

-

9

E. coli

-

1 (100.0)

1

Total

156 (86.6)

24 (13.4)

180

Row percentage.

a
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Table 2. The characteristics of patients and the relationships of risk factors with clinical response.
n

Cure (%)a

Male

111

71 (64.0)

Female

47

27 (57.4)

<65

90
68

64 (71.1)
34 (50.0)

0.007b

Hospitalization in ICU*

136

80 (58.8)

0.039b

Underlying ultimately fatal disease

55

23 (41.8)

0.000b

Nephrotoxicity due to colistin

80

45 (56.2)

0.130b

Previous renal disease

27

6 (22.2)

0.000b

Previous antibiotic usage

56

28 (50.0)

0.021b

Central venous catheter

76

43 (56.6)

0.174b

Mechanical ventilation

116

69 (59.5)

0.274b

Total parenteral nutrition

76

38 (50.0)

0.003b

Steroid usage

10

7 (70.0)

0.591c

Hemodialysis

16

6 (37.5)

0.033b

Sex
Age

≥65

P-value
0.440b

*ICU: Intensive care unit.
a
Row percentage, bChi-square test, cFisher exact test.
Table 3. Microbiological and clinical cure of colistin therapy.
Therapy

n

Microbiological cure (%)a

Clinical cure (%)a

Monotherapy

6

3 (50.0%)

3 (50.0%)

Dual therapy

64

24 (37.5%)

41 (64.1%)

Triple therapy

88

28 (31.8%)

54 (61.4%)

Total

158

55 (34.8%)

98 (62.0%)

0.560

0.826

P-valueb
Row percentage, bChi-square test.

a

Table 4. Related factors in patients who did not respond to colistin.
Risk factor

OR (95% CI)

P-value

Ultimately fatal disease

6.5 (1.6–26.1)

<0.0001

Underlying renal disease

9.1 (1.9–41.9)

<0.0001

Total parenteral nutrition

4.5 (1.9–10.3)

0.003

Variables included in the model: Dependent variable: Cure (yes: 0, no: 1); Age (ref, <65 years: 0);
Ultimately fatal disease (ref, no: 0); Hospitalization in ICU (ref, no: 0); Underlying renal disease (ref, no:
0); Hemodialysis (ref, no: 0); Total parenteral nutrition (ref, no: 0); Previous antibiotic usage (ref, no: 0).
OR: Odds ratio; CI: Confidence interval.
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which might be related to different clinical characteristics
of patients. The clinical response rate in our study was
62%, similar to the literature (12–17). Our study sample
(n = 158) was larger than most of the previous ones and
included critically ill patients who had been hospitalized
(86.1%) in the ICU.
The risk factors for clinical outcome were reported
as bacteremia, acute respiratory distress syndrome, and
high APACHE II score in previous studies (17–20). In
our study, multivariate analyses showed that underlying
ultimately fatal disease, previous renal diseases, and total
parenteral nutrition were important independent risk
factors for worse clinical response.
There were a number of in vitro studies that
demonstrated a synergistic activity when colistin was
combined with rifampicin or amikacin. In animal studies,
comparisons of colistin monotherapy with combinations
with rifampicin, carbenicillin, piperacillin, and imipenem
for treatment of P. aeruginosa, A. baumannii, or Escherichia
coli infections were evaluated and decreased mortality
rates were determined with these combinations (21).
Although the data are promising for in vitro and
animal studies, there is no clinical proof of an advantage
for colistin combination therapy and future clinical studies
are necessary (21–24). In a recent study from Turkey,
colistin-carbapenem, colistin-sulbactam, and colistin with
other antibiotic combinations were investigated for XDR
Acinetobacter blood stream infections and significance
was not found according to 14-day survival and clinical or
microbiological outcome (25).
In our study, colistin was administered as monotherapy
in six patients (3.8%) and with different antibiotic groups
for the remainder. We determined no difference in terms
of effectiveness between monotherapy and combination
colistin therapies, probably due to the low power value
of the statistical comparison (power value = 8.8%) (26).
A small number of patients with colistin monotherapy
might be a limitation of our study, and we think that
clinical studies with larger numbers of patients given
both monotherapy and combination colistin therapies are
mandatory.

Rates of nephrotoxicity in recent studies have ranged
from 6% to 55% and this great difference can be explained
by various definitions of acute kidney injury. Risk factors
for nephrotoxicity found in different studies included older
age, preexisting renal insufficiency, hypoalbuminemia,
hyperbilirubinemia, and concomitant use of nonsteroidal
antiinflammatory drugs, calcineurin inhibitors, or other
nephrotoxic agents like vancomycin (1,5,6).
We determined nephrotoxicity in 80 (50.6%) patients
during colistin treatment and older age was the statistically
significant risk factor associated with nephrotoxicity.
The usage of other nephrotoxic drugs, underlying renal
disease, and colistin dosage were not found as important
risk factors for induction of renal injury.
The mechanism for colistin-related nephrotoxicity
is unknown as there are rare studies about the
pharmacokinetics and pharmacodynamics of the drug.
It is dose-dependent and usually reversible following
discontinuation of therapy, so it is thought to be caused
by acute tubular necrosis (ATN) like aminoglycosideand amphotericin-related nephropathies (5,27). Cheng
et al. (14), determined nephrotoxicity in 14% of their
115 patients on colistin. After the discontinuation of
colistin, the reversibility of toxicity was shown. In our
study, renal function tests returned to baseline levels with
discontinuation of colistin in 35 (43.75%) patients and
dose reduction in 21 (26.25%) patients.
The other adverse effect, neurotoxicity (0%–7%), is less
common than nephrotoxicity. Clinical manifestations of
neurotoxicity are dizziness, muscle weakness, paresthesias,
partial deafness, visual disturbances, vertigo, confusion,
hallucinations, seizures, ataxia, and neuromuscular
blockade (28,29). Neurotoxicity was evaluated in only
conscious and nonsedated patients in our study and was
not determined in any of them.
In conclusion, the effect of nephrotoxicity on the
clinical response of colistin for MDR/XDR-GN bacterial
infections was not determined in our study. We suggest
that colistin may be a valuable therapeutic option for MDR/
XDR-GN bacterial infections with close monitorization
of renal functions, especially for older and critically ill
patients.
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